A Cost Analysis of the 1-2-3 Pap Intervention by Rabarison, Kristina M. et al.
Frontiers in Public Health Services and 
Systems Research 
Volume 4 Number 3 Article 3 
May 2015 
A Cost Analysis of the 1-2-3 Pap Intervention 
Kristina M. Rabarison 
Centers for Disease Control and Prevention, krabarison@cdc.gov 
Rui Li 
Division of Diabetes Translation, Centers for Disease Control and Prevention, RuiLi@cdc.gov 
Connie L. Bish 
Division of Population Health, Centers for Disease Control and Prevention, aez2@cdc.gov 
Robin C. Vanderpool 
University of Kentucky, robin@kcr.uky.edu 
Richard A. Crosby 
University of Kentucky, richard.crosby@uky.edu 
Mehran S. Massoudi 
Division of Population Health, Centers for Disease Control and Prevention, mrm8@cdc.gov 
Follow this and additional works at: https://uknowledge.uky.edu/frontiersinphssr 
 Part of the Health Economics Commons, Health Services Research Commons, Public Health 
Education and Promotion Commons, and the Women's Health Commons 
Recommended Citation 
Rabarison KM, Li R, Bish CL, Vanderpool RC, Crosby RA, Massoudi MS. A cost analysis of the 1-2-3 Pap 
intervention. Front Public Health Serv Sys Res 2015; 4(3):45–50. DOI: 10.13023/FPHSSR.0403.02. 
This Article is brought to you for free and open access by the Center for Public Health Systems and Services 
Research at UKnowledge. It has been accepted for inclusion in Frontiers in Public Health Services and Systems 
Research by an authorized administrator of UKnowledge. For more information, please contact 
UKnowledge@lsv.uky.edu. 
A Cost Analysis of the 1-2-3 Pap Intervention 
Abstract 
Background: Cervical cancer places a substantial economic burden on our healthcare system. The three-
dose human papillomavirus (HPV) vaccine series is a cost-effective intervention to prevent HPV infection 
and resultant cervical cancer. Despite its efficacy, completion rates are low in young women aged 18 
through 26 years. 1-2-3 Pap is a video intervention tested and proven to increase HPV vaccination 
completion rates. 
Purpose: To provide the full scope of available evidence for 1-2-3 Pap, this study adds economic evidence 
to the intervention’s efficacy. This study tested the economies of scale hypothesis that the cost of 1-2-3 
Pap intervention per number of completed HPV vaccine series would decrease when offered to more 
women in the target population. 
Methods: Using cost and efficacy data from the Rural Cancer Prevention Center, a cost analysis was done 
through a hypothetical adaptation scenario in rural Kentucky. 
Results: Assuming the same success rate as in the efficacy study, the 1-2-3 Pap adaptation scenario 
would cover 1000 additional women aged 18 through 26 years (344 in efficacy study; 1346 in adaptation 
scenario), and almost three times as many completed series (130 in efficacy study; 412 in adaptation 
scenario) as in the original 1-2-3 Pap efficacy study. 
Implications: Determination of the costs of implementing 1-2-3 Pap is vital for program expansion. This 
study provides practitioners and decision makers with objective measures for scalability. 
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ervical cancer, 91% of which is attributable to human papillomavirus (HPV), places a 
substantial economic burden on our healthcare system.1,2 Estimated direct medical care costs 
for HPV-associated diseases (e.g., cervical cancer screening and treatment) are $8 billion 
annually (2010 USD).1 The three-dose HPV vaccine series through age 26 years is a cost-effective 
intervention to prevent HPV infection and resultant cervical cancer.3 Despite its effectiveness, 
completion rates are low in women aged 18 through 26 years, especially for those living in 
underserved areas such as Appalachian Kentucky.4,5 Improving HPV vaccine completion rates, 
defined as the rate of receiving the third dose, is important and women aged 18 through 26 years are 
an identified target population.4,5 1-2-3 Pap is a video-based intervention created and tested by the 
Rural Cancer Prevention Center (RCPC) to increase HPV vaccination completion rates among 
women aged 18 through 26 years, residing in the eight-county Kentucky River Area Development 
District (KRADD) who already received the first dose.5  
 
Determining the cost of implementing 1-2-3 Pap is vital for program expansion. This study tested 
the economies-of-scale hypothesis that the cost of 1-2-3 Pap intervention per number of completed 




The 1-2-3 Pap efficacy study, which has been described elsewhere,5 was composed of 344 women 
who received the first dose of the HPV vaccine series (initiation dose). Results showed that women 
who watched the video were 2.44 more likely to complete the HPV vaccine series than those who 
did not.5  
 
To test the intervention’s scalability, a cost analysis was conducted using expenditure reports from 
the RCPC. Subsequently, cost changes were assessed for 1-2-3 Pap through a hypothetical 
adaptation scenario within the KRADD. Institutional review board approval was not needed 
because data were obtained from federal reporting documents used to monitor the Centers for 
Disease Control Prevention Research Centers program. Costs included in the study were for 
resources used to recruit the original 1-2-3 Pap efficacy study participants, to create and disseminate 
the video, and to administer HPV vaccine doses.  
 
The adaptation scenario sample size was estimated by multiplying the number of women aged 18 
through 26 years in the KRADD (N = 5930; 2010 U.S. Decennial Census) with the national HPV 
vaccination initiation rate (22.7%).4 This resulted in an estimated 1346 women who would watch the 
video when receiving the first dose. During the efficacy study, the adherence (Dose 2) and 
completion (Dose 3) rates among those who watched the 1-2-3 Pap video were 61.2% and 43.3%, 
respectively.5 Specific adherence and completion rates for rural Kentucky are not available. 
Therefore, for the adaptation scenario, the national adherence and completion rates were used for 
women aged 18 through 26 years (17.6% and 12.7%, respectively).4 Assuming that the intervention 
is as effective in the adaptation scenario as it was in the efficacy study, the adherence (43.6%) and 
completion (30.6%) rate differences between the 1-2-3 Pap efficacy study and the national rates were 
used to estimate the adaptation scenario uptake rates.4,5  
 
Perspectives. Costs were estimated from a provider perspective, which includes only the direct 
costs.  
 
Time Frame and Analytic Horizon. A 28-month time frame and analytic horizon were assumed, 
which was the length of the 1-2-3 Pap efficacy study (September 2010–December 2012).5  
 
Direct Costs. Direct costs included 1-2-3 Pap efficacy study participant incentives, video creation 
and dissemination, and clinical costs associated with administering HPV vaccine doses. The video 
C 
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creation costs included script development, studio time, editing, production services, and local talent 
fees for six actors.5 The intervention was disseminated via laptop computers and administered by a 
community health nurse who conducted participant intake interviews during the 1-2-3 Pap efficacy 
study.5 The clinical costs included vaccine doses two and three, and office visits. The cost of initial 
doses was excluded because it was a requirement for inclusion in the 1-2-3 Pap program.5 Office 
visit costs were estimated using the percentage of Kentucky adults with private and Medicaid 
insurance coverage, the Medicaid physician fee for outpatient services in Kentucky, and the 
Medicaid-to-private-health-insurance conversion rate (Appendix). 
 
In the adaptation scenario, laptop costs and community health nurse time were excluded because the 
video would be shared and recommended to women while receiving their initial HPV vaccine dose. 
Further, the video is available on YouTube, making it easy to share via other social media platforms 
such as Facebook.  
 
Total Cost. From a provider perspective, the total 1-2-3 Pap efficacy study cost was calculated as 
the sum of the direct cost. The total 1-2-3 Pap adaptation cost would only include the clinical costs. 
Total cost per series completed was estimated. Sensitivity analysis was used to estimate the costs if 





The adaptation scenario population had 5930 eligible women aged 18 through 26 years. Among 
these, assuming the same effectiveness as in the efficacy study, the estimated doses administered 
were: 1346 initial, 587 adherence, and 412 completion doses.  
 
1-2-3 Pap Efficacy Study Cost. The total 1-2-3 Pap efficacy study cost was $115,655.00 or $890 
per series completed (n=130). Table 1.  
 
Table 1: 1-2-3 Pap efficacy study costs per number of 3-dose HPV vaccine series completion, among 
women aged 18–26 years who watched the video, in rural Kentucky 




N of Units  
(B) 
 
Total Cost ($) 
 (C = A x B) 
Trial Participant Incentives     
Gift Cards 26 344 Cards 8,944  
Food - Used to Recruit Participants 5 350 Servings 1,750  
Video Creation      
Studio, Editing, and Production Services 27,428 1 Production 27,428  
Local Talent Fees 67 6 Actors 402  
Video Dissemination      
Community Health Nurse  48 211 Nurses 10,128  
Laptops (1/4 value) 278 4 Laptops 1,112  
Clinical      
Adherence Dose (Dose 2) 137 229 Doses 31,373  
Completion Dose (Dose 3) 137 130 Doses 17,810  
Office Visit - Medicaid 39 122 Visits 4,760  
Office Visit - Private Insurance  52 230 Visits 11,948  
Total Intervention Cost  115,655  
Intervention Cost per Completed Series      890  
 
48




1-2-3 Pap Adaptation Cost. The estimated total cost of the adaptation scenario was $160,280, or 
$389 per series completed (n = 412). Table 2.  
 
Table 2: Hypothetical adaptation costs per number of 3-dose HPV vaccine series completion, among 
women aged 18–26 years who watched the video, in rural Kentucky 
                                                      Estimated Adaptation Cost (N = 1346) 


















Total Cost  
($) 












Total Cost  
($) 
(C = A x B)
 
Clinical         
Adherence Dose  
(Dose 2) 
137 587 80,419 381 52,186 175 23,972 
Completion Dose  
(Dose 3) 
137 412 56,444 267 36,512 121 16,596 
Office Visit: Medicaid 20 340 6,793 220 4,402 101 2,014 
Office Visit: Private 
Insurance  
26 639 16,623 414 10,773 190 4,927 
Total Intervention Cost 160,280  103,873  47,509 
Intervention Cost per 
Completed Series  
  389  390      392 
a. Total cost, assuming the adaptation is 100% as effective as the efficacy study 
b. Total cost, assuming the adaptation is 75% as effective as the efficacy study  





This analysis provides practitioners and decision makers with objective measures of the costs of 
implementing 1-2-3 Pap in a larger population. The results supported the hypothesis that 1-2-3 Pap 
implementation cost would decrease as it is offered to more people. Assuming the same success rate 
as in the efficacy study, the adaptation scenario would cover 1000 additional women aged 18 
through 26 years (344 in efficacy study; 1346 in adaptation scenario), and almost three times as many 
completed series (130 in efficacy study; 412 in adaptation scenario) as in the original 1-2-3 Pap 
efficacy study. 1-2-3 Pap’s total cost would decrease from $890 to $389 per women completing three 
doses. Considering that the annual cost of cervical cancer screening and treatment ranges from 
$30,775 to $52,731 per case (2010 USD),1 the estimated $890 investment per completed series might 
be worthwhile. Findings likely translate to other rural areas, because local actors and community 
members were used in the video to ensure cultural relevancies.  
 
The next analytical steps are implementation cost estimations for a large urban county and the state 
of Kentucky, and a cost-effectiveness analysis (CEA). The CEA will provide insight into 
implementation costs and benefits such as healthcare costs avoided from preventing cervical cancer. 
The 1-2-3 Pap efficacy study showed that women who watched the video were 2.44 times more 
likely to complete the series than those who did not. However, initiation rates remain low among 
this target population, and increased initiation remains a priority.4,5 
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SUMMARY BOX 
 
What is already known about this topic? The 1-2-3 Pap intervention is an informational and 
instructional video created and tested to increase HPV vaccination completion rates among women aged 
18 through 26 years residing in Appalachian Kentucky who had already received an initiation dose. 
Women randomized to watch the 1-2-3 Pap video in addition to the standard of care (an educational 
pamphlet and telephone reminder calls for doses 2 and 3) were 2.44 times more likely to complete the 
HPV vaccine series than those in the standard-of-care-only group.  
 
What is added by this report? Intervention estimated costs are critical to understanding the full scope of 
available evidence. This study adds economic evidence of the effectiveness of the 1-2-3 Pap video.  
 
What are the implications for public health practice, policy, and research? Determination of the 
costs of implementing 1-2-3 Pap is vital for program expansion. This study provides practitioners and 
decision makers with objective measures for scalability. The results supported the hypothesis that 1-2-3 
Pap implementation cost would decrease as it is offered to more people. Findings likely translate to other 
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APPENDIX 
 
Items  Data Sources 
Studio, editing, and 
production services 
University of Kentucky Rural Cancer Prevention Center  
Local talent fees University of Kentucky Rural Cancer Prevention Center 
Laptop  University of Kentucky Rural Cancer Prevention Center purchased four laptop computers 
for the efficacy study. Only a fourth of the value was applied to the intervention 
implementation cost estimation, based on the assumption that the laptops were used for 
other efficacy study related activities.  
Community health nurse University of Kentucky Rural Cancer Prevention Center  
HPV vaccine dose cost  CDC’s HPV Vaccine Information for Young Women (fact sheet) 
(http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women.htm)   
Office visit, Medicaid Estimated using the outpatient Medicaid reimbursement physician fee in Kentucky - $39 
per visit (http://www.chfs.ky.gov/dms/fee.htm)  
Office visit, private 
insurance  
Estimated using the average private insurance coverage (64%) and Medicaid rates (34%) 
for Kentucky (http://kff.org/other/state-indicator/adults-19-64/) and the Medicaid to 
private insurance coverage rate (Private insurance coverage = 0.75 * Medicaid rate) (Ku 
L. Medical and dental care utilization and expenditures under Medicaid and private health 
insurance, 2009 [http://mcr.sagepub.com/content/66/4/456.refs]) 
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